• ABOUT US
    ▼
    • Our Vision
    • Leadership Team
  • OUR RESEARCH
    ▼
    • Our Approach
    • Publications
    • Conferences
  • PROGRAMS
    ▼
    • Pipeline
    • VIS649 Sibeprenlimab
    • VIS171
    • VIS513
  • FOR PATIENTS
    ▼
    • Clinical Trials
    • IgA Nephropathy
  • CAREERS
    ▼
    • Open Positions & Benefits
    • Our Culture
    • Co-op program
  • Contact

Visterra

We Bring Better Biologics to Life

  • ABOUT US
    • Our Vision
    • Leadership Team
  • OUR RESEARCH
    • Our Approach
    • Publications
    • Conferences
  • PROGRAMS
    • Pipeline
    • VIS649 Sibeprenlimab
    • VIS171
    • VIS513
  • FOR PATIENTS
    • Clinical Trials
    • IgA Nephropathy
  • CAREERS
    • Open Positions & Benefits
    • Our Culture
    • Co-op program
  • Contact

Conferences

Conferences

Assessment of Resistance Development to Therapeutic mAb VIS410 in an International Phase 2a Study (VIS410-202) in Adults with Uncomplicated Influenza A Infection

November 13, 2018 | International Society for Influenza and Respiratory Viruses (ISIRV) Antiviral Drug Development Conference
Narayan, et. al.

Assessment of Resistance Development to Therapeutic mAb VIS410 in an International Phase 2a Study (VIS410-202) in Adults with Uncomplicated Influenza A Infection

Kristin Narayan, Bharathi Sundaresh, Emily Helger, Saskia Smits, Rienk Jeeninga, Susan Sloan, David Oldach

>SEE POSTER

VIS649 reduces serum IgA levels in NHPs dose dependently: PK/PD exposure-response modeling for translation to treatment of IgA Nephropathy

October 23, 2018 | American Society of Nephrology (ASN)
Sloan, et. al.

VIS649 reduces serum IgA levels in NHPs dose dependently: PK/PD exposure-response modeling for translation to treatment of IgA Nephropathy

Susan E Sloan, Frank Engler, Kristy J Szretter, James R Myette, Kristin Narayan, Bharathi L Sundaresh, Brian J G Pereira

>SEE POSTER

Preclinical safety and scalability of VIS649 production for clinical trials for the treatment of IgA nephropathy

October 23, 2018 | American Society of Nephrology (ASN)
Miller, et. al.

Preclinical safety and scalability of VIS649 production for clinical trials for the treatment of IgA nephropathy

Veronica M Miller, Susan E Sloan, Kristy J Szretter, James R Myette , Emily Helger, Brian J G Pereira

A pre-clinical evaluation of an APRIL targeting antibody strategy in grouped ddY mice and non-human primates and correlation to pathogenic and immune related mechanisms

September 27, 2018 | International IgAN Symposium
Myette, et. al.

A pre-clinical evaluation of an APRIL targeting antibody strategy in grouped ddY mice and non-human primates and correlation to pathogenic and immune related mechanisms

James R Myette, Toshiki Kano, Hitoshi Suzuki, Susan E Sloan, Yusuke Suzuki, Brian J G

>SEE POSTER

Safety, pharmacokinetics and pharmacodynamics of VIS649, a humanized monoclonal IgG2 targeting APRIL, for the treatment of IgAN in a GLP toxicology study in Cynomolgus Monkeys

September 27, 2018 | International IgAN Symposium
Sloan, et. al.

Safety, pharmacokinetics and pharmacodynamics of VIS649, a humanized monoclonal IgG2 targeting APRIL, for the treatment of IgAN in a GLP toxicology study in Cynomolgus Monkeys

Susan E Sloan, James R Myette, Bharathi L Sundaresh, Zachary Shriver, David Oldach, Brian J G Pereira

>SEE POSTER

Developments in Computational-Based Methods for Antibody Design

September 27, 2018 | Discovery on target

Developments in Computational-Based Methods for Antibody Design

Andrew Wollacott

Structure-Based Epitope Targeting for Engineering Functional Antibodies Against Nav1.7 for Pain

April 30, 2018 | PEGS

Structure-Based Epitope Targeting for Engineering Functional Antibodies Against Nav1.7 for Pain

Luke Robinson

Population Pharmacokinetic and Viral Dynamic Modeling of VIS410, aMonoclonal Antibody Against Influenza A Virus in a Human Challenge Model

February 23, 2018 | International Society for Influenza and Respiratory Viruses (ISIRV) Antiviral Drug Development Conference
Patel, et. al.

Population Pharmacokinetic and Viral Dynamic Modeling of VIS410, aMonoclonal Antibody Against Influenza A Virus in a Human Challenge Model

Kashyap Patel, Patrick Smith, Susan Sloan, Georgina Dall, Mark Lovern, Jose Travejo, Ellie Hershberger

>SEE POSTER

VIS410, a Broad-Spectrum, Anti-Influenza A Monoclonal Antibody in Clinical Development Demonstrates Activity Against Recent Vaccine, Seasonal, and H7N9 Strains of Influenza

February 23, 2018 | International Society for Influenza and Respiratory Viruses (ISIRV) Antiviral Drug Development Conference
Narayan, et. al.

VIS410, a Broad-Spectrum, Anti-Influenza A Monoclonal Antibody in Clinical Development Demonstrates Activity Against Recent Vaccine, Seasonal, and H7N9 Strains of Influenza

Kristin Narayan, Kristy Szretter, Emily Helger, Bharathi Sundaresh, Zachary Shriver, David Oldach, Susan Sloan

>SEE POSTER

Model-based Clinical Efficacy Prediction and Study Design Support for VIS410, a Novel Neutralizing mAb, in Combination with Oseltamivir, in Hospitalized Patients with Influenza A

February 23, 2018 | International Society for Influenza and Respiratory Viruses (ISIRV) Antiviral Drug Development Conference
Xiong, et. al.

Model-based Clinical Efficacy Prediction and Study Design Support for VIS410, a Novel Neutralizing mAb, in Combination with Oseltamivir, in Hospitalized Patients with Influenza A

Yuan Xiong, Mark Lovern, Patrick Smith, Russell Wada, Susan Sloan, Ellie Hershberger

>SEE POSTER
  • « Previous Page
  • 1
  • 2
  • 3

© 2023 Visterra, Inc. Terms of usePrivacy PolicySite Design: Fassino/Design